» Articles » PMID: 37304619

Gut Dysbiosis Following Organophosphate, Diisopropylfluorophosphate (DFP), Intoxication and Saracatinib Oral Administration

Overview
Date 2023 Jun 12
PMID 37304619
Authors
Affiliations
Soon will be listed here.
Abstract

Organophosphate nerve agents (OPNAs) act as irreversible inhibitors of acetylcholinesterase and can lead to cholinergic crisis including salivation, lacrimation, urination, defecation, gastrointestinal distress, respiratory distress, and seizures. Although the OPNAs have been studied in the past few decades, little is known about the impact on the gut microbiome which has become of increasing interest across fields. In this study, we challenged animals with the OPNA, diisopropylfluorophosphate (DFP, 4mg/kg, s.c.) followed immediately by 2mg/kg atropine sulfate (i.m.) and 25mg/kg 2-pralidoxime (i.m.) and 30 minutes later by 3mg/kg midazolam (i.m.). One hour after midazolam, animals were treated with a dosing regimen of saracatinib (SAR, 20mg/kg, oral), a src family kinase inhibitor, to mitigate DFP-induced neurotoxicity. We collected fecal samples 48 hours, 7 days, and 5 weeks post DFP intoxication. 16S rRNA genes (V4) were amplified to identify the bacterial composition. At 48 hours, a significant increase in the abundance of and decrease in the abundance of were observed in DFP treated animals. At 7 days there was a significant reduction in and , but a significant increase in in the DFP groups compared to controls. The taxonomic changes at 5 weeks were negligible. There was no impact of SAR administration on microbial composition. There was a significant DFP-induced reduction in alpha diversity at 48 hours but not at 7 days and 5 weeks. There appeared to be an impact of DFP on beta diversity at 48 hours and 7 days but not at 5 weeks. In conclusion, acute doses of DFP lead to short-term gut dysbiosis and SAR had no effect. Understanding the role of gut dysbiosis in long-term toxicity may reveal therapeutic targets.

Citing Articles

Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare.

Vasanthi S, Massey N, Nair S, Mochel J, Showman L, Thippeswamy T Front Vet Sci. 2023; 10:1297221.

PMID: 38026620 PMC: 10666625. DOI: 10.3389/fvets.2023.1297221.


Peripheral and central effects of NADPH oxidase inhibitor, mitoapocynin, in a rat model of diisopropylfluorophosphate (DFP) toxicity.

Meyer C, Rao N, Vasanthi S, Pereira B, Gage M, Putra M Front Cell Neurosci. 2023; 17:1195843.

PMID: 37416507 PMC: 10320212. DOI: 10.3389/fncel.2023.1195843.

References
1.
Guignet M, Dhakal K, Flannery B, Hobson B, Zolkowska D, Dhir A . Persistent behavior deficits, neuroinflammation, and oxidative stress in a rat model of acute organophosphate intoxication. Neurobiol Dis. 2019; 133:104431. PMC: 6754818. DOI: 10.1016/j.nbd.2019.03.019. View

2.
Sharma S, Carlson S, Puttachary S, Sarkar S, Showman L, Putra M . Role of the Fyn-PKCδ signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy. Neurobiol Dis. 2017; 110:102-121. PMC: 5753797. DOI: 10.1016/j.nbd.2017.11.008. View

3.
Jett D . Chemical toxins that cause seizures. Neurotoxicology. 2012; 33(6):1473-1475. DOI: 10.1016/j.neuro.2012.10.005. View

4.
Helmstaedter C, Witt J . Epilepsy and cognition - A bidirectional relationship?. Seizure. 2017; 49:83-89. DOI: 10.1016/j.seizure.2017.02.017. View

5.
Chong J, Liu P, Zhou G, Xia J . Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat Protoc. 2020; 15(3):799-821. DOI: 10.1038/s41596-019-0264-1. View